The literature data consistently show a negative prognostic impact of KRAS and BRAF mutations in MSI patients on long-term outcomes such as RFS and OS, emphasizing the adverse effects of these mutations in metastatic disease rather than in operable cases. The gene discussed is BRAF; the disease is metastatic neoplasm.